VivoSeq
Infectious Disease

Vulvovaginal Candidiasis

26

Pipeline Programs↗

5

Active Trials↗

12

Companies Involved↗

Vulvovaginal Candidiasis is an emerging landscape with 26 programs across 12 companies. The most active players are NovaDigm Therapeutics, Inc., Matinas BioPharma Nanotechnologies, Inc., Pfizer. 5 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

87/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

NovaDigm Therapeutics, Inc.

2 programs

Phase 2M

Matinas BioPharma Nanotechnologies, Inc.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

31 of 32 classified programs — the dominant modality here.

3%ALL OTHERSVaccine13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed20 · 54%
Unknown status9 · 24%
Recruiting3 · 8%
Withdrawn3 · 8%
Not yet recruiting1 · 3%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

37 trials

Vulvovaginal Candidiasis in Canadian Females
Recruiting·UUniversity of Manitoba·Phase 1·NCT04930107·105 enrolled
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
Recruiting·MMaastricht University Medical Center·Phase 3·NCT05367089·252 enrolled
Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
Recruiting·PpH-D Feminine Health LLC·Phase 3·NCT07109869·400 enrolled
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
Active, not recruiting·LLimmaTech Biologics AG·Phase 1/2·NCT06190509·251 enrolled
Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）
Not yet recruiting·—·N/A·NCT07044947·3,000 enrolled
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
Completed·PProbionov·Phase 3·NCT02251093·350 enrolled
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
Completed·PPadagis LLC·N/A·NCT00803738·572 enrolled
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Completed·SScynexis, Inc.·Phase 3·NCT04029116·440 enrolled
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Completed·SScynexis, Inc.·Phase 2·NCT03253094·186 enrolled
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Completed·SScynexis, Inc.·Phase 3·NCT05399641·150 enrolled
Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Completed·—·Phase 2·NCT01144286·229 enrolled
Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Completed·PPeking University Shenzhen Hospital·Phase 4·NCT02180100·140 enrolled
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
Completed·PPeking University Shenzhen Hospital·Phase 4·NCT02180828·240 enrolled
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
Completed·SScynexis, Inc.·Phase 3·NCT03734991·376 enrolled
Diabetes Mellitus and Vulvovaginal Candidiasis
Completed·IIndian Council of Medical Research·Phase 3·NCT00353561·100 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)